We observed that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes characterize advanced CML disease and poor imatinib respondents. Here, PRDM2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.